Mitoxantrone-Lance

"Miloxantrone LENS" is a chemotherapeutic agent from a group of antitumor drugs of synthetic origin of different groups, used for the treatment of malignant neoplasms using intravenous (intramuscular) infusion. Developed and produced in Russia by Lance Pharm. The international non-proprietary name of Mitoxantrone is Mitoxantrone. Miloxanthone LENS is available in an injection solution containing 2 mg of active substance per milliliter of liquid.

Indications for use of Mitoxantrone LENS are breast cancer, tumors of the liver, prostate and ovaries of a malignant nature, as well as chronic and acute leukemia, erythromycosis in adults, ascites cancer and others

Mitoxantrone is a synthetic anticancer drug that acts by inhibiting phosphorylation of the cyclin D-CDK-4/6 complex (CDK4, CDK6).

The drug is used for various malignant diseases:

Breast cancer, accompanied by the presence of distant or regional metastases. Liver cancer, ovarian cancer Prostate cancer, including the hormone-resistant final stage, is accompanied by pain. Non-Hodgkin's lymphoma Acute myeloid and promyeloid leukemia. Erythromyelosis when other drugs are ineffective. Ascites in cancer.

Contraindications are hypersensitivity to the drug, intrathecal injection. Also contraindications are pregnancy, breastfeeding and childhood (under 18 years). The drug should be administered under the supervision of a physician. After administration of mitoxantrone, it is necessary to regularly monitor a complete blood count (cellular composition), as well as tests that determine the level of hemoglobin/hematocrit/leukocytes/platelets. During therapy, the following may also occur: hypersensitivity; pancytopenic agranulocyosis;